top of page
CiPA, the Comprehensive In Vitro Proarrythmia Assay, is a new paradigm for drugs' pre-clinical cardiac safety assessment, initiated and developed with global efforts (www.cipaproject.org):
DRIVEN by a suite of mechanistically based in vitro assays coupled to in silico reconstructions of cellular cardiac ion channel electrophysiologic activity, CiPA assay will inform the potential proarrhythmia risk of a test substance and contribute to the design of clinical drug safety study.
bottom of page